Market Research Life Sciences Market Research Medical Devices Market Research Stents Market Research

Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Best Price Guarantee Length Publisher Published Date SKU
from $4,000 142 Pages GlobalData July, 2022 GBDT17376132
Best Price Guarantee
Price from $4,000
Length 142 Pages
Publisher GlobalData
Published Date July, 2022
SKU GBDT17376132

Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Summary

GlobalData's Medical Devices sector report, “Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.

Scope

  • Extensive coverage of the Drug Eluting Stents (DES) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


  • About GlobalData
  • Introduction
    • Drug Eluting Stents (DES) Overview
  • Products under Development
    • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
      • Table Figure 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
      • Table Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
    • Drug Eluting Stents (DES) - Pipeline Products by Territory
      • Table Figure 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
      • Table Drug Eluting Stents (DES) - Pipeline Products by Territory
    • Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
      • Table Figure 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
      • Table Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
    • Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
      • Table Figure 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
      • Table Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
    • Drug Eluting Stents (DES) - Ongoing Clinical Trials
      • Table Figure 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
      • Table Drug Eluting Stents (DES) - Ongoing Clinical Trials
  • Drug Eluting Stents (DES) - Pipeline Products under Development by Companies
    • Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
      • Table Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
    • Drug Eluting Stents (DES) - Companies Pipeline Products by Stage of Development
      • Table Drug Eluting Stents (DES) - Companies Pipeline Products by Stage of Development
  • Drug Eluting Stents (DES) Companies and Product Overview
    • Abbott Vascular Inc Company Overview
      • Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table XIENCE BIOPRIME - Product Status
        • Table XIENCE BIOPRIME - Product Description
        • Table Xience Max - Product Status
        • Table Xience Max - Product Description
        • Table Xience SBA Everolimus Eluting Coronary Stent System - Product Status
        • Table Xience SBA Everolimus Eluting Coronary Stent System - Product Description
        • Table XIENCE Thinman DES - Product Status
        • Table XIENCE Thinman DES - Product Description
        • Table ZoMaxx Drug Eluting Coronary Stent System - Product Status
        • Table ZoMaxx Drug Eluting Coronary Stent System - Product Description
        • Table Abbott Vascular Inc - Ongoing Clinical Trials Overview
        • Table Xience SBA Everolimus Eluting Coronary Stent System - A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
        • Table Xience SBA Everolimus Eluting Coronary Stent System - A Prospective, Multi-center, Single-blinded, Randomized Trial of the Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-II
    • Adcomp Technologies Inc. Company Overview
      • Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Dual Drug Eluting Stent - Product Status
        • Table Dual Drug Eluting Stent - Product Description
    • Advanced Bifurcation Systems Inc Company Overview
      • Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table ABS Stenting System - Drug Eluting Stent - Product Status
        • Table ABS Stenting System - Drug Eluting Stent - Product Description
    • Aeon Bioscience Company Overview
      • Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
        • Table Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
        • Table Drug Eluting Stent - Product Status(Aeon Bioscience)
        • Table Drug Eluting Stent - Product Description(Aeon Bioscience)
    • B. Braun Melsungen AG Company Overview
      • B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Coroflex DEBlue - Product Status
        • Table Coroflex DEBlue - Product Description
    • Biosensors International Group Ltd Company Overview
      • Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table BioFreedom Ultra - Product Status
        • Table BioFreedom Ultra - Product Description
        • Table Biosensors International Group Ltd - Ongoing Clinical Trials Overview
        • Table BioFreedom Ultra - A Pilot Study Registry of the BioFreedom BA9 Ultra Drug-Coated Coronary Stent for Patients With ST Elevation Myocardial Infarct (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
        • Table BioFreedom Ultra - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
        • Table BioFreedom Ultra - A Randomized Controlled Comparison Between One Versus More than Six Months of Dual Antiplatelet Therapy after Biolimus A9-eluting Stent Implantation
        • Table BioFreedom Ultra - A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding
        • Table BioFreedom Ultra - Asian Registry of the BioFreedom BA9 Drug-Coated Coronary Stent for Patients with ST Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
        • Table BioFreedom Ultra - BioFreedom Ultra Stent in Hong Kong All Comers Registry
        • Table BioFreedom Ultra - Comparison of Polymer-free Cobalt-Chromium Thin Drug-coated Stents with Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy with Conventional 12-Month Dual Antiplatelet Therapy
        • Table BioFreedom Ultra - Evaluation of Effectiveness and Safety of Biofreedom Family Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
        • Table BioFreedom Ultra - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
        • Table BioFreedom Ultra - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
        • Table BioFreedom Ultra - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
    • Biotronik AG Company Overview
      • Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Coronary Stent System - Product Status
        • Table Coronary Stent System - Product Description
    • Biotronik SE & Co KG Company Overview
      • Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
        • Table ProGenic Pimecrolimus-eluting Coronary Stent System - Product Status
        • Table ProGenic Pimecrolimus-eluting Coronary Stent System - Product Description
    • Boston Scientific Corp Company Overview
      • Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table JACTAX Drug Eluting Stent - Product Status
        • Table JACTAX Drug Eluting Stent - Product Description
        • Table SYNERGY 48 Stent - Product Status
        • Table SYNERGY 48 Stent - Product Description
        • Table SYNERGY XD Stent - Product Status
        • Table SYNERGY XD Stent - Product Description
        • Table TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System - Product Status
        • Table TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System - Product Description
        • Table Boston Scientific Corp - Ongoing Clinical Trials Overview
        • Table SYNERGY XD Stent - Evaluation of Effectiveness and Safety of Synergy XD Stent in Routine Clinical Practice: A Multicenter, Prospective Observational Study
    • Cardionovum GmbH Company Overview
      • Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table DEBLIMUS - Product Status
        • Table DEBLIMUS - Product Description
        • Table PROTECT - Product Status
        • Table PROTECT - Product Description
        • Table ReNATURAL (M) - Product Status
        • Table ReNATURAL (M) - Product Description
        • Table ReNATURAL (P) - Product Status
        • Table ReNATURAL (P) - Product Description
    • Cardiorev Pte Ltd (Inactive) Company Overview
      • Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Peptide-Eluting Coronary Stent - Product Status
        • Table Peptide-Eluting Coronary Stent - Product Description
    • Columbia University Company Overview
      • Columbia University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Columbia University Pipeline Products & Ongoing Clinical Trials Overview
        • Table C3 Exoenzyme Coated Stent - Product Status
        • Table C3 Exoenzyme Coated Stent - Product Description
    • Concept Medical Inc Company Overview
      • Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Abluminus DES+ - Product Status
        • Table Abluminus DES+ - Product Description
        • Table Abluminus NP - Product Status
        • Table Abluminus NP - Product Description
        • Table Concept Medical Inc - Ongoing Clinical Trials Overview
        • Table Abluminus DES+ - A Multicenter, Prospective, Study to Evaluate the Safety and Effcacy of the Abluminus DES+ in an All-Comers Population
        • Table Abluminus DES+ - A Post Market Registry of Abluminus Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetes Mellitus
        • Table Abluminus DES+ - A Randomized Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus eluting DES for Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: an Investigator-initiated Pilot Study
        • Table Abluminus DES+ - ABLUMINUS Below the Knee (BTK) Drug Eluting Stent (DES) Registry (ABLUMINUS BTK) - First in Men
        • Table Abluminus DES+ - Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes Mellitus Global - ABILITY Diabetes Global
        • Table Abluminus DES+ - Randomized Trial Investigating Clinical Outcomes of Two Sirolimus-Eluting Stents in Diabetes Mellitus
    • Cordis Corp Company Overview
      • Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Corio Pimecrolimus-Eluting Stent - Product Status
        • Table Corio Pimecrolimus-Eluting Stent - Product Description
        • Table Cypher Elite - Product Status
        • Table Cypher Elite - Product Description
        • Table NEVO Sirolimus-Eluting Coronary Stent - Product Status
        • Table NEVO Sirolimus-Eluting Coronary Stent - Product Description
        • Table Next Generation Coronary Stent - Product Status
        • Table Next Generation Coronary Stent - Product Description
    • DISA Vascular (Pty) Ltd Company Overview
      • DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Stellium Stent - Product Status
        • Table Stellium Stent - Product Description
    • Elixir Medical Corp Company Overview
      • Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
        • Table DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
        • Table Myolimus Eluting Coronary Stent - Durable Polymer - Product Status
        • Table Myolimus Eluting Coronary Stent - Durable Polymer - Product Description
    • Envision Scientific Pvt Ltd Company Overview
      • Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Paclitaxel Eluting Stent - Product Status
        • Table Paclitaxel Eluting Stent - Product Description
    • I.B.S. S.p.A. Company Overview
      • I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
        • Table I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Drug Eluting Stent - Product Status(I.B.S. S.p.A.)
        • Table Drug Eluting Stent - Product Description(I.B.S. S.p.A.)
    • InspireMD Inc Company Overview
      • InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MGuard Drug Eluting Stent - Product Status
        • Table MGuard Drug Eluting Stent - Product Description
    • JW Medical Systems Ltd Company Overview
      • JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Excel II DES - Product Status
        • Table Excel II DES - Product Description
        • Table JW Medical Systems Ltd - Ongoing Clinical Trials Overview
        • Table Excel II DES - A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery Lesions (CREDIT II Trial)
    • Kaneka Corp Company Overview
      • Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table MAHOROBA Stent - Product Status
        • Table MAHOROBA Stent - Product Description
    • MangoGen Pharma Inc Company Overview
      • MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Gene-Delivering Stent - Product Status
        • Table Gene-Delivering Stent - Product Description
    • Medinol Ltd Company Overview
      • Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Elunir Elastomer Drug Eluting Stent - 38mm - Product Status
        • Table Elunir Elastomer Drug Eluting Stent - 38mm - Product Description
        • Table Elunir Elastomer Drug Eluting Stent - 44mm - Product Status
        • Table Elunir Elastomer Drug Eluting Stent - 44mm - Product Description
        • Table IoNIR Ridaforolimus-Eluting Coronary Stent System - Product Status
        • Table IoNIR Ridaforolimus-Eluting Coronary Stent System - Product Description
        • Table Medinol Ltd - Ongoing Clinical Trials Overview
        • Table IoNIR Ridaforolimus-Eluting Coronary Stent System - IonMAN Trial-First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
    • Medlogics Device Corp (Inactive) Company Overview
      • Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
        • Table COBRA-Q Drug Eluting Stent - Product Status
        • Table COBRA-Q Drug Eluting Stent - Product Description
        • Table SYNERGY - Product Status
        • Table SYNERGY - Product Description
    • Medtronic Plc Company Overview
      • Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Drug Filled Stent - Product Status
        • Table Drug Filled Stent - Product Description
        • Table Onyx Frontier DES - Product Status
        • Table Onyx Frontier DES - Product Description
        • Table Resolute Onyx DES - Bifurcation Lesions - Product Status
        • Table Resolute Onyx DES - Bifurcation Lesions - Product Description
        • Table Resolute Onyx DES - DAPT - Product Status
        • Table Resolute Onyx DES - DAPT - Product Description
        • Table Medtronic Plc - Ongoing Clinical Trials Overview
        • Table Resolute Onyx DES - Bifurcation Lesions - A Post-approval Study of the Medtronic Resolute Onyx Zotarolimuseluting Coronary Stent System
    • MicroPort Scientific Corp Company Overview
      • MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Fantasy Drug-Eluting Stent - Product Status
        • Table Fantasy Drug-Eluting Stent - Product Description
        • Table Firebird Pro+ - Product Status
        • Table Firebird Pro+ - Product Description
        • Table Firehawk Plus - Product Status
        • Table Firehawk Plus - Product Description
    • MIV Therapeutics Inc Company Overview
      • MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Smart-2 DES - Product Status
        • Table Smart-2 DES - Product Description
        • Table Smart-3 DES - Product Status
        • Table Smart-3 DES - Product Description
    • NuVascular Technologies Inc Company Overview
      • NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table NuSpun DE Stent Sheath - Product Status
        • Table NuSpun DE Stent Sheath - Product Description
    • Relisys Medical Devices Ltd Company Overview
      • Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Corel + C Drug Eluting Stent - Product Status
        • Table Corel + C Drug Eluting Stent - Product Description
    • REVA Medical Inc Company Overview
      • REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status
        • Table ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description
        • Table ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold - Product Status
        • Table ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold - Product Description
    • Sahajanand Medical Technologies Pvt Ltd Company Overview
      • Sahajanand Medical Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sahajanand Medical Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Product Status
        • Table Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Product Description
        • Table Sahajanand Medical Technologies Pvt Ltd - Ongoing Clinical Trials Overview
        • Table Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - A Randomized Controlled Trial to Compare the Safety and Efficacy of Sirolimus-eluting Biodegradable Polymer Ultra-thin Stent (SUPRAFLEX Cruz) and Everolimus-eluting Biodegradable Polymer Stent (SYNERGY) in Treatment for Three-vessel Coronary Artery Disease: Multivessel Talent
        • Table Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
        • Table Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Sirolimus-eluting Coronary Stent System in the Treatment of All-comer Patients with Coronary Artery Disease
        • Table Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Post-market Registry to Evaluate the Safety and Efficacy of the the SUPRAFLEX CRUZ Sirolimus Eluting Coronary Stent System in the Treatment of an Octo- and Nonagenerian All-comer Patient Cohort with Coronary Artery Disease - The Cruz Senior Study
        • Table Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Ultrathin Drug Eluting Stents for Patients with Left-main, Bifurcation, Chronic Total Occlusion, or In-stent Restenosis Coronary Lesion in Real Life: The ULTRA a Multicenter Study
    • Shanghai BIOMAGIC Medical Device Co Ltd Company Overview
      • Shanghai BIOMAGIC Medical Device Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Shanghai BIOMAGIC Medical Device Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table BIOMAGIC Biroresorbable Coronary Stent - Product Status
        • Table BIOMAGIC Biroresorbable Coronary Stent - Product Description
    • Shanghai MicroPort Medical Group Co Ltd Company Overview
      • Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - Product Status
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - Product Description
        • Table Shanghai MicroPort Medical Group Co Ltd - Ongoing Clinical Trials Overview
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - A Prospective Multi-center Open-label Controlled Trial of Comparison 3 Versus 12 Months of Dual Anti-platelet Therapy after Implantation of Firehawk Sirolimus Target- eluting Stent in Patients with Stable Coronary Artery Disease
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - A Prospective Multicenter Post Market Trial to Assess the Safety and Effectiveness of the Firehawk Rapamycin Target Eluting Cobalt Chromium Coronary Stent System (Firehawk Stent System) for the Treatment of Atherosclerotic Lesion(s)
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - A Prospective, Multicenter, Single-arm Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in Patients with Coronary Artery Stenosis
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - A Prospective, Open Label, Multi-center Trial of Firehawk Coronary Stent System in the Treatment of Coronary Chronic Total Artery Occlusion Lesion(S) by Optical Coherent Tomography (OCT) and Coronary Angiography
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - Assessment of In-stent Intimal Repair and Vessel Reaction After Firehawk Sirolimus Eluting Stent Implantation of STEMI Subjects - An Optical Coherence Tomography (OCT) Study
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - Optical Coherence Tomography Compared with Intravascular Ultrasound or Quantitative Coronary Analysis to Guide Stent Implantation in the Treatment of Moderate-tosevere Calcified Lesion in Coronary Artery
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of Firehawk Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: A Prospective, Multicenter, Single-group Study
        • Table Firehawk Rapamycin Target Eluting Coronary Stent System - The Safety and Effectiveness Evaluation of New Specifications (38mm) of Firehawk Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: A Prospective, Multicenter, Single-group Study
    • Sino Medical Sciences Technology Inc Company Overview
      • Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table BuMA Supreme DES - Product Status
        • Table BuMA Supreme DES - Product Description
        • Table Supreme HT Drug-Eluting Stent - Product Status
        • Table Supreme HT Drug-Eluting Stent - Product Description
        • Table Sino Medical Sciences Technology Inc - Ongoing Clinical Trials Overview
        • Table BuMA Supreme DES - A Prospective, Multicenter First-in-man Trial Program in China to Evaluate the Efficacy and Safety of Buma Supreme (Eg Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Subjects with De Novo Coronary Lesions, RCT Trial
        • Table BuMA Supreme DES - A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients with de Novo Coronary Lesions, OPC Trial
        • Table Supreme HT Drug-Eluting Stent - A Prospective, Multi-center, Single-group Target Value Post-marketing Clinical Study to Evaluate the Safety and Effectiveness of the HT Supreme Drug-eluting Stent System in the Treatment of "Real-world" Patients with Coronary Heart Disease
        • Table Supreme HT Drug-Eluting Stent - Non-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated with Unrestricted Use of the Healing-targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy after 1-month of Dual-antiplatelet Therapy
    • Stentys SA Company Overview
      • Stentys SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table Stentys SA Pipeline Products & Ongoing Clinical Trials Overview
        • Table STENTYS Paclitaxel-Eluting Stent - Product Status
        • Table STENTYS Paclitaxel-Eluting Stent - Product Description
    • Svelte Medical Systems Inc Company Overview
      • Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table DIRECT RX - Product Status
        • Table DIRECT RX - Product Description
        • Table SLENDER IDS - Product Status
        • Table SLENDER IDS - Product Description
        • Table Svelte Medical Systems Inc - Ongoing Clinical Trials Overview
        • Table SLENDER IDS - OPTIMIZE Sirolimus-eluting Coronary Stent Systems Pharmacokinetics (PK) Study
        • Table SLENDER IDS - The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
        • Table DIRECT RX - OPTIMIZE Sirolimus-eluting Coronary Stent Systems Pharmacokinetics (PK) Study
        • Table DIRECT RX - The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
    • Terumo Corp Company Overview
      • Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table ULTIMASTER NAGOMI - Product Status
        • Table ULTIMASTER NAGOMI - Product Description
        • Table Ultimaster Tansei - Product Status
        • Table Ultimaster Tansei - Product Description
        • Table Terumo Corp - Ongoing Clinical Trials Overview
        • Table Ultimaster Tansei - A Prospective Study, Single-arm, Multicentre, Observational to Evaluate Safety and Effectiveness of Stent Ultimaster Tansei Coronary Stent in Complex Coronary Lesions
        • Table Ultimaster Tansei - Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
        • Table Ultimaster Tansei - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
        • Table Ultimaster Tansei - Zotarolimus Eluting Stent Versus Sirolimus Eluting Stent in High Bleeding Risk Angioplasty
    • Terumo Interventional Systems Company Overview
      • Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview
        • Table Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview
        • Table Next Generation Ultimaster Drug Eluting Bioresorbable Scaffold - Product Status
        • Table Next Generation Ultimaster Drug Eluting Bioresorbable Scaffold - Product Description
        • Table Next Ultimaster Metallic Drug Eluting Stent - Product Status
        • Table Next Ultimaster Metallic Drug Eluting Stent - Product Description
    • TissueGen Inc Company Overview
      • TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cardiovascular Stent - Product Status
        • Table Cardiovascular Stent - Product Description
    • Translumina Therapeutics LLP Company Overview
      • Translumina Therapeutics LLP Pipeline Products & Ongoing Clinical Trials Overview
        • Table Translumina Therapeutics LLP Pipeline Products & Ongoing Clinical Trials Overview
        • Table VIVO ISAR-Sirolimus Eluting Coronary Stent System - Product Status
        • Table VIVO ISAR-Sirolimus Eluting Coronary Stent System - Product Description
    • University of Strathclyde Company Overview
      • University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
        • Table Drug-Eluting Stent - Product Status
        • Table Drug-Eluting Stent - Product Description
    • VasoTech Inc. Company Overview
      • VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table PowerStent Coro DES - Product Status
        • Table PowerStent Coro DES - Product Description
  • Drug Eluting Stents (DES)- Recent Developments
    • Jul 08, 2022: Cordis Names Bryan Loo President of Asia-pacific Region
    • Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director
    • May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results
    • May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase
    • Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022
    • Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022
    • Feb 10, 2022: Contego Medical Announces Hiring of Steve MacKinnon, Chief Commercialization Officer
    • Jan 04, 2022: Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference
    • Dec 09, 2021: Cordis appoints Dr. George Adams to Chief Medical Officer
    • Dec 08, 2021: Dr Jens von Lackum appointed to the Management Board of B. Braun SE
    • Dec 02, 2021: FDA: August 7, 2019 update: Treatment of peripheral arterial disease with paclitaxelcoated balloons and paclitaxel-eluting stents potentially associated with increased mortality
    • Nov 18, 2021: MicroPort RehabTech TherMotion Cryo-Thermo compression device approved for marketing in China
    • Nov 08, 2021: Boston Scientific Announces Upcoming Conference Schedule
    • Nov 04, 2021: Terumo Corp Half Yearly Results For the Period 30 September 2021
    • Nov 02, 2021: Cordis Names Muscari President Of The Americas
    • Oct 27, 2021: Boston Scientific Announces Results For Third Quarter 2021
    • Oct 07, 2021: Construction begins on 280,000-square-meter MicroPort MegaFactory and global medical experience center
    • Sep 15, 2021: Opto Circuits Announces Unaudited Standalone Financial Results For The First Quarter Ended 30th June 2021
    • Sep 09, 2021: Boston Scientific Announces 2021 Investor Day Meeting
    • Aug 17, 2021: Opto Circuits (India) Announces Financial Results for the Year Ended 31st March 2021
    • Aug 17, 2021: Opto Circuits (India) Announces Board Changes
    • Aug 04, 2021: Terumo Revises its Full-Year Financial Guidance for FY2021
    • Aug 04, 2021: Terumo Corp. Announces Consolidated Financial Results for the First Quarter Ended June 30, 2021
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

$4,000
$8,000
$12,000

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings